Alnylam Pharmaceuticals-Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2025, Alnylam Pharmaceuticals (ALNY) reported revenue of $773.69 million, up 17.3% over the same period last year. EPS came in at$ 0.32, compared to $0.56 in the year-ago quarter.The reported revenue represents a surprise of +14.96% over the Zacks Consensus Estimate of$ 673 million. With the consensus EPS estimate being -$0.03, the EPS surprise was +1166.67%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...